GNPX GENPREX INC Company Mergers 8-K Filing 2025 - Joint Ventures On April 28, 2025, Genprex, Inc. announced an exclusive patent license agreement with NYU Langone Health for its Reqorsa® Gene Therapy, aimed at treating mesothelioma, which could improve the company's oncology portfolio. The therapy showed promising preclinical results indicating significant tumor suppression potential.Get access to all SEC 8-K filings of the GENPREX INC